Researchers may have discovered a new targeted intervention for Barth Syndrome. The new study shows the benefits of targeted intervention with an iPLA2-VIA inhibitor that prevents a major symptom of the disease- cardiolipin deficiency.
Researchers may have discovered a new targeted intervention for Barth Syndrome. The new study shows the benefits of targeted intervention with an iPLA2-VIA inhibitor that prevents a major symptom of the disease- cardiolipin deficiency.